Literature DB >> 22433752

Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report.

Marc L Berger1, Nancy Dreyer, Fred Anderson, Adrian Towse, Art Sedrakyan, Sharon-Lise Normand.   

Abstract

OBJECTIVE: In both the United States and Europe there has been an increased interest in using comparative effectiveness research of interventions to inform health policy decisions. Prospective observational studies will undoubtedly be conducted with increased frequency to assess the comparative effectiveness of different treatments, including as a tool for "coverage with evidence development," "risk-sharing contracting," or key element in a "learning health-care system." The principle alternatives for comparative effectiveness research include retrospective observational studies, prospective observational studies, randomized clinical trials, and naturalistic ("pragmatic") randomized clinical trials.
METHODS: This report details the recommendations of a Good Research Practice Task Force on Prospective Observational Studies for comparative effectiveness research. Key issues discussed include how to decide when to do a prospective observational study in light of its advantages and disadvantages with respect to alternatives, and the report summarizes the challenges and approaches to the appropriate design, analysis, and execution of prospective observational studies to make them most valuable and relevant to health-care decision makers. RECOMMENDATIONS: The task force emphasizes the need for precision and clarity in specifying the key policy questions to be addressed and that studies should be designed with a goal of drawing causal inferences whenever possible. If a study is being performed to support a policy decision, then it should be designed as hypothesis testing-this requires drafting a protocol as if subjects were to be randomized and that investigators clearly state the purpose or main hypotheses, define the treatment groups and outcomes, identify all measured and unmeasured confounders, and specify the primary analyses and required sample size. Separate from analytic and statistical approaches, study design choices may strengthen the ability to address potential biases and confounding in prospective observational studies. The use of inception cohorts, new user designs, multiple comparator groups, matching designs, and assessment of outcomes thought not to be impacted by the therapies being compared are several strategies that should be given strong consideration recognizing that there may be feasibility constraints. The reasoning behind all study design and analytic choices should be transparent and explained in study protocol. Execution of prospective observational studies is as important as their design and analysis in ensuring that results are valuable and relevant, especially capturing the target population of interest, having reasonably complete and nondifferential follow-up. Similar to the concept of the importance of declaring a prespecified hypothesis, we believe that the credibility of many prospective observational studies would be enhanced by their registration on appropriate publicly accessible sites (e.g., clinicaltrials.gov and encepp.eu) in advance of their execution. Copyright Â
© 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Mesh:

Year:  2012        PMID: 22433752     DOI: 10.1016/j.jval.2011.12.010

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  51 in total

Review 1.  Randomized controlled trials and neuro-oncology: should alternative designs be considered?

Authors:  Alireza Mansouri; Samuel Shin; Benjamin Cooper; Archita Srivastava; Mohit Bhandari; Douglas Kondziolka
Journal:  J Neurooncol       Date:  2015-08-22       Impact factor: 4.130

2.  Frequency and Impact of Adverse Events in Patients Undergoing Surgery for End-Stage Ankle Arthritis.

Authors:  Daniel C Norvell; Jane B Shofer; Sigvard T Hansen; James Davitt; John G Anderson; Donald Bohay; J Chris Coetzee; John Maskill; Michael Brage; Michael Houghton; William R Ledoux; Bruce J Sangeorzan
Journal:  Foot Ankle Int       Date:  2018-05-31       Impact factor: 2.827

3.  Control Outcomes and Exposures for Improving Internal Validity of Nonrandomized Studies.

Authors:  Stacie B Dusetzina; M Alan Brookhart; Matthew L Maciejewski
Journal:  Health Serv Res       Date:  2015-01-19       Impact factor: 3.402

Review 4.  Clinical Comparative Effectiveness Research Through the Lens of Healthcare Decisionmakers.

Authors:  Eboni G Price-Haywood
Journal:  Ochsner J       Date:  2015

5.  A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.

Authors:  Marc L Berger; Bradley C Martin; Don Husereau; Karen Worley; J Daniel Allen; Winnie Yang; Nicole C Quon; C Daniel Mullins; Kristijan H Kahler; William Crown
Journal:  Value Health       Date:  2014-03       Impact factor: 5.725

6.  Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed.

Authors:  Karin C Berger; Brian M Feldman; Joan Wasserman; Wolfgang Schramm; Victor Blanchette; Kathelijn Fischer
Journal:  Haematologica       Date:  2016-03       Impact factor: 9.941

Review 7.  Benchmarking Observational Analyses Against Randomized Trials: a Review of Studies Assessing Propensity Score Methods.

Authors:  Shaun P Forbes; Issa J Dahabreh
Journal:  J Gen Intern Med       Date:  2020-03-19       Impact factor: 5.128

8.  Stage- and age-adjusted cost-effectiveness analysis of laparoscopic surgery in rectal cancer.

Authors:  Javier Mar; Ane Anton-Ladislao; Oliver Ibarrondo; Arantzazu Arrospide; Santiago Lázaro-Aramburu; Nerea Gonzalez; Marisa Bare; Antonio Escobar; Maximino Redondo; José M Quintana
Journal:  Surg Endosc       Date:  2019-05-28       Impact factor: 4.584

Review 9.  Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.

Authors:  Gregory Kruse; Bruce J O Wong; Mei Sheng Duh; Patrick Lefebvre; Marie-Hélène Lafeuille; John M Fastenau
Journal:  Pharmacoeconomics       Date:  2015-10       Impact factor: 4.981

10.  Incident user cohorts for assessing medication cost-offsets.

Authors:  Bruce Stuart; F Ellen Loh; Pamela Roberto; Laura Miller
Journal:  Health Serv Res       Date:  2014-03-15       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.